Abbott Program for Expanding Access to Treatment
Abbott has a longstanding commitment to the fight against HIV/AIDS and has implemented five practical measures to ensure the company's medicines are as broadly available as possible: Innovation with the Needs of the Developing World in Mind: Abbott developed the lopinavir/ritonavir tablet, the only co-formulated protease inhibitor tablet that does not require refrigeration and can be taken with or without food - two important advances in delivering HIV medicine, especially in developing countries. Broad Registration: The heat-stable tablet formulation of lopinavir/ritonavir has been filed, is available or has been approved in 170 countries. The new, lower-strength tablet formulation of lopinavir/ritonavir, which is suitable for pediatric use, has been filed, is available or has been approved in 124 countries. Abbott intends to make the lower-strength tablet available or approved in every country where the adult tablet is available. In January 2010, Abbott received approval for a new, heat-stable tablet formulation of its protease inhibitor ritonavir, and the company intends to register the new ritonavir tablet as broadly worldwide as the lopinavir/ritonavir tablet. Commitment to the Treatment of Children with HIV: Abbott has a longstanding commitment to the treatment of children with HIV. The company has made the liquid formulation of lopinavir/ritonavir available in the developing world since 2001. The new, lower-strength lopinavir/ritonavir tablet complements the liquid formulation and was first launched in Africa in 2007, even before it was available in developed countries. Investment in Consistent Quality Manufacturing: Abbott has invested hundreds of millions of dollars in the development of the heat-stable tablet formulations and sufficient manufacturing capacity to ensure they can be supplied to all who need them at universally high quality standards. Affordable Pricing: Since 2002, our HIV medicines have been available in all 69 African and least developed countries at prices that are among the lowest for branded or generic protease inhibitors. Philanthropic Measures: As part of the company's broad efforts to expand access to health care, Abbott and the company's philanthropic foundation, the Abbott Fund, have invested more than USD 175 million to improve the lives of more than 1 million people affected by HIV/AIDS in Africa and elsewhere in the developing world.